Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02327884
Other study ID # 150051
Secondary ID 15-D-0051
Status Recruiting
Phase
First received
Last updated
Start date April 3, 2015
Est. completion date April 1, 2032

Study information

Verified date May 8, 2024
Source National Institutes of Health Clinical Center (CC)
Contact Eileen M Pelayo
Phone (301) 594-3097
Email eileen.pelayo@nih.gov
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: - Salivary glands in and around the mouth and throat make saliva. Salivary gland disorders can affect a person s quality of life. Studying people who have a disease that affects their salivary gland(s) may teach researchers about the disorders and their genetics. Objectives: - To study salivary gland diseases and disorders. To collect data and samples from people with salivary gland problems and their relatives. Eligibility: - People more than 4 years old who have or are suspected to have a disease involving salivary glands. - Their relatives more than 4 years old. - Healthy volunteers 18 years or older. Design: - Participants may be screened with: - Medical history - Physical exam - Blood and urine tests - General oral and dental history and exam - Saliva collection - Eye exam and test for dry eyes - Health questionnaires (adults) - Biopsy of some minor salivary glands. A small incision will be made on the inside of the lower lip and several tiny salivary glands will be removed. - Participants will have 2 3 visits. These may include: - Repeats of some screening tests - Ultrasounds of some glands. Researchers will put some gel on the face, then press on it with a smooth wand. - Adults may have other biopsies - A small catheter inserted into the opening of the parotid gland duct on the inside of the cheek. A saline solution (in a syringe) will fill the duct. - Swishing a saltwater solution in the mouth for 10 seconds and then spitting into a cup - Scrapings collected from teeth, tongue, and cheeks


Description:

This protocol is intended to allow disease-specific investigations in subjects with presentations of diseases with salivary gland involvement and will enable the collection of data, biological fluids and tissue samples from those subjects, their family members and normal controls, in order to assist our studies of understanding salivary gland disease pathophysiology. The exocrine salivary glands, by secreting saliva, play a critical role in the homeostasis of the oral cavity, which is the initial part of the gastrointestinal track. Several diseases including Parkinson s and systemic amyloidosis can be diagnosed through biopsies of easily accessible salivary glands. Moreover, several drugs and systemic diseases cause salivary gland hypofunction through unknown mechanisms. We may evaluate participants with complaints of dry mouth to determine the cause and severity of their salivary gland dysfunction and their possible eligibility for other NIDCR protocols. Salivary secretions have antibacterial, lubricating, remineralizing, digestive, buffering and cleansing properties. Impaired function of these glands can cause an increase in tooth decay; a variety of oral hard and soft tissue changes, with painful, burning or ulcerated or oral mucosa; problems chewing, swallowing and speaking; and diminished taste and smell. This protocol will provide us with the opportunity to learn from a variety of pathologies that involve directly or indirectly the salivary glands, expand our knowledge about these disorders and provide access to patients of interest for research, teaching, and clinical experience. Information obtained through this protocol may lead to potential innovative therapeutic studies. In addition to its role in investigating individuals who are of interest to the Sjogren s syndrome (SS) and Salivary Gland Dysfunction Unit of the MPTB of NIDCR, this protocol can provide a possible avenue for enrolling subjects from other NIH programs or other NIH protocols that exhibit signs or symptoms associated with the salivary glands dysfunction.


Recruitment information / eligibility

Status Recruiting
Enrollment 1150
Est. completion date April 1, 2032
Est. primary completion date April 1, 2032
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 4 Years to 100 Years
Eligibility - INCLUSION CRITERIA: - Persons older than 4 years of age, affected with or suspected of being affected with a disease/disorder involving the salivary glands or who is a relative of a person who is affected with these diseases/disorders. Or, - Persons 18 years or older with active hepatitis with or without sicca symptoms and patients undergoing immunotherapy with an immune checkpoint inhibitor for oral cancer. Specific to patients undergoing immunotherapy with an immune checkpoint inhibitor for threatment of oral cancer, these patients will be seen before and after check point inhibitor therapy which will coincide with 4 weeks (+/-2 weeks) before and again immediately before (+/- 2 weeks) definitive oral cancer treatment initiation (e.g., surgical resection, etc.). Or, - Healthy persons age 18 or older, who agree to have blood, urine, saliva or tissue samples collected and studied. EXCLUSION CRITERIA: - Anyone not able to give consent/assent or parental/guardian consent - NIH employees who report directly to the principal investigator - Significant concurrent medical condition or other circumstances that may affect the participant s ability to tolerate or complete the study, such as concurrent chemotherapy or bleeding disorders. - Specific only to the immune checkpoint inhibitor patients, oral cancer as a serious concurrent medical condition, will not serve as an exclusion criteria. - Moreover, these immune checkpoint inhibitor subjects, if unable to tolerate the study procedures, such as salivary gland biopsies, saliva collections, and/or oral exams, will be excluded as determined by the Principal Investigator. - Additional exclusion criteria for Healthy Volunteers (HV): - Pregnancy - Sicca Symptoms - HIV, hepatitis B or C infection - Chronic medical illness, other than well-controlled hypertension or hyperlipidemia - Chronic use of medications, with the exception of oral contraception, hormone replacement therapy, aspirin, antihypertensives and antilipemics

Study Design


Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Dental and Craniofacial Research (NIDCR)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary hypothesis generating hypothesis generating hypothesis generating
See also
  Status Clinical Trial Phase
Completed NCT06326723 - Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects Phase 1
Recruiting NCT00001367 - Diagnosis and History Study of Patients With Different Neurological Conditions
Completed NCT02699710 - Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects Phase 1
Completed NCT02231892 - Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study N/A
Not yet recruiting NCT06441916 - Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions Phase 1
Completed NCT03771586 - A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects Phase 1
Not yet recruiting NCT06337422 - Bioequivalence Study of Generic Celecoxib 200 mg Capsules Phase 1
Completed NCT03302182 - Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects Phase 1
Completed NCT05049343 - Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants Phase 1
Recruiting NCT01629108 - Normal Values in Hearing and Balance Testing
Completed NCT02947854 - Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant Phase 1
Completed NCT02534870 - Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects Phase 1
Completed NCT02224053 - Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers Phase 1
Completed NCT01676584 - A Study of Single Dose RO6811135 in Healthy Volunteers Phase 1
Completed NCT01684891 - A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers Phase 1
Completed NCT01697436 - A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets Phase 1
Completed NCT01711762 - A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers Phase 1
Completed NCT01579149 - A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent Phase 1
Completed NCT02547259 - Influence of Emotion in a Test Run Forgetfulness N/A
Completed NCT01414881 - Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects Phase 1